Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
False statement. IPIX is NOT a Pink Sheet stock. IPIX is traded on the OTCBB.
There are two primary platforms for the listing of over-the-counter securities. Nasdaq operates the OTCBB which acts as a quotation service for over-the-counter sales and the OTCBB requires companies listed to have updated financial reports filed with the SEC, banking regulators and insurance regulators.
Only one adverse event currently holding up P2 trial in UK for AZ.
Yet to date over 17,000 people have been vaccinated in this phase of the trial.
The article says the delay may take a month before results are known and trial can resume.
I find such a delay totally uncalled for - kind of like suspending a war because a soldier got injured and they don't know if he tripped or came into contact with some new form of biological gas.
One person and testing stops?? Asinine IMO.
How many of those 17000 who received the vaccine were saved from dying? Yet only one reaction (unknown if due to vaccine) and they shut it down. Doesn't make sense to me.
I hold no shares of AZ and my disgust at how trials are run has been consistent since day 1 for ALL trials, not just IPIX trials.
Independent research and an article in Oncology Reports identify a drug that showed it was able to arrest cell growth and cause cell death for AML cells with a less toxic drug profile. AML is the cause of 1/4 to 1/3 of all leukemia cases.
Effective, safe, now that seems to make one think The Cancer Foundation would want to help push that drug into commercialization, or at least further study, to the benefit of tens of thousands of patients a year. Just one or two million dollars would do wonders to help further it.
But IMO the odds are next to nil they take any note of it. IMO they have become their own animal and cures may put them out of work. Hope I am just cynical and this is not the case. We will see.
Flying high, Falcon, flying high!!
Always appreciate hearing your take as you were in the trenches. Nice to have someone bring reality into the picture. Like I said, I think most civil servants are like the police, dedicated workers. But there are a number (and sadly I think most of those at the top) that have allowed this situation to become what it is (in conjunction with BS Congressional laws). I often paint with too broad a brush.
I thought the Regeneron trial failed just recently.
We seem to view things differently as I interpret your post as saying you are blaming the shortcomings of the FDA on a lack of people and assets.
I read the articles as laying the blame on the people that run the FDA, the inherently self-promoting interests of many of them (or at least those in high positions that can affect a drug's advancement thru the system), and the useless and wasteful degree of document evidence required to get a drug approved that these aforementioned people have brought about in the system resulting in near impossible time and cost to bring a drug to market.
Just like we say FINRA is useless until they start throwing those caught cheating in jail for a LONG time, the same must be said of those in the FDA running their pay-to-play games.
I do realize it is a lot like the current police situation in that a few (at least possibly only a few)are harming the reputations of the vast majority. But both situations are the same in that those that are caught doing grievous wrong must be made to pay a high price in regards to punishment and IMO that means LONG jail terms.
Yesterday, +.0075 Today -.0075
Oh so predictable.
But the summer doldrums are now over.
Let's see what's in store for the rest of 2020. Exciting times.
Let's hope articles like this get action instituted to question the workings of the FDA and make it more reasonable to bring new drugs to market:
https://www.nationalreview.com/2020/09/fda-st...nnovation/
I believe the days when IPIX could be toyed with at will are about to come to an end.
I sincerely hope we do not get a pre-open PR no matter what day Leo releases it. If we do, it only favors the MMs as they can screw with it and establish their positions doing pre-trading.
Why not reward those who have followed this for years, and especially lately watching constantly, by posting the PR right at opening or even 30 minutes after?
IPIX down .0045 Fri, up .0045 Mon, and down .0045 today w/ about 20 minutes to go. No wonder the B bands are tight.
It has become quite common that whatever gain or loss IPIX incurs one day is EXACTLY negated the next day. They aren't even trying to hide their actions. Example - up .0045 today, down .0045 Friday.
I thought they had already looked into eye and ear drops and they are on the back burner for right now due to other more promising indications.
Only question is whether B may be too strong (cause too much eye pressure) and may have to be weakened for eye drops or something of that nature. Not sure, just some ramblings I heard.
Are you forgetting this is a pandemic and the old BS timelines should be disregarded?
Maybe we would get immediate approval if we renamed it Rems...Brilacidin.
From what I hear on various sites, I must be one of the only believers in IPIX that has no remorse or worry when those I have told about it (and who are now in the red, some deep in the red) bitch about it. Why?
I told them right off the bat that biotech was the riskiest sector of investing possible. I stressed they only invest what they could afford to lose. I told them there was a major effort by unknown bodies to try and sabotage the future of IPIX, IMO these being BPs whose drugs are going to be made irrelevant by IPIXs.
On the other hand, I point to where IPIX is today, which IMO is right on the cusp of being wildly successful. IMO you have to risk big to win big. IPIX is one of the few that allows that dream to become a reality. I have staked a lot on this becoming true and hold little worry that it will fail.
I tell them don't bother me until we get word back on the upcoming human trial results for CV19. IMO that will be the first nut to crack with the OM and IBD trial successes following close behind. I tell them by the end of the year they could (not will, but could) see a return on their investment that will buckle their knees and by next Mar or so the return could make the end of the year price look like peanuts. A sure thing, no, but at this stage of the game a very, very, very good chance to happen.
So I end it with them at this juncture to just follow IPIX CLOSELY. When the news starts (and I believe the publicity starts in Sept) and things start percolating they should consider diving in and then it is their own responsibility to decide when to get out. As of now, anyone that invested within the last 18 months had the chance to earn a great return on their investment if they sold when prices were in the .50 range. Their greed kept them in, that is not my problem.
If some people lose a little money on IPIX, I will feel bad for them. If some never had the chance to make a fortune, I will feel terrible that I didn't allow them that opportunity by at least making it known to them.
I don't badger people to buy it, I just mention my investment if asked and say it is something they may want to follow. I do affirm I heartily recommend them to at least follow it.
As you are well aware much more than others, IPIX/Leo seems to be taking a very refined path thru the CV investigation and the development of Brilacidin so that it will be able to achieve it's full potential. His low profile, fiscal conservatism, little publicity, non-fluff PRs, tactical changes such as the recent appointment of Dr. DeGrado as a scientific advisor, the grant request in conjunction with an RBL for a PAN-CORONA investigation, etc, etc has shown tremendous restraint and professionalism IMO.
The attacks on him, his character, and his managerial abilities have turned into a sad caricature to the point of being embarrassing to those making the remarks.
Sept is the month IMO that the MMs lose control of the ability to manipulate the share price as they have been able to do for nearly a decade.
Good news, MAJOR publicity, major backing from medical professionals, and the need to advance CV treatments much quicker than up to the present will all cause Brilacidin to shine across the USA and most of the world.
We have another month before advancement in other indications for additional trials but they will start in Q4 per my belief.
IPIX is going to be the "overnight success story / medical sensation" that took a decade to get to the position it is in today.
It will be amazing once a book is written, as I believe will be done, telling the story of IPIX and most will be shocked at how close it came to being bankrupted by those trying to quash it's medical marvels.
I agree as well and it all stems from the CV investigatory trials.
Contact Leo. We know there are sachets available, so ask about how to get your relative into the trial (as I believe one is coming in Q4) or possibly even for a mercy use (forgot what it is called when one can use a drug before FDA approval)
The OM P3 will be important to IPIX, but CV dwarfs it in what it should be able to do to advance IPIX. Not knocking OM, but CV is the homerun hitter compared to OM being a bunt single hitter.
CV and its testing is what is going to provide many, many opportunities for Brilacidin to be tested across many, many areas of medicine at the top universities, labs, BPs (complementary to their drugs), and non-USA sites.
It will lead Brilacidin into lung, kidney, head, and many other areas of medical need whose yearly revenues are over 100 times as large as OM. It also puts Brilacidin on the map of governmental medical agencies to include BARDA, INH, DOD, and others.
With the addition of Dr. DeGrado, I believe we have also opened up possibilities for numerous other uses for Brilacidin. Cannot say enough how important for the company adding Dr. D to our scientific advisor team will prove to be.
It's all good for IPIX from my vantage point.
The 300+ SI number for B came from an IPIX PR.
Leo was not going to steal the thunder from the GMU researcher and give the exact SI number as IMO she will most likely be the lead investigator for the PAN-CORONA investigation grant which they co-submitted with IPIX and Brilacidin is her career-making research drug.
Anybody really think Leo is going to put himself at risk by stating a non-correct SI number that will easily be verifiable from the soon to be published pre-review peer article by GMU?
If the SI isn't equivalent for each drug regarding a specific virus, then what good is it?
Science is supposed to be hard facts, not interpretations, so anything other than apples to apples comparing is useless.
I personally don't see the comparison between B and Rems... being anything but a moot point at this juncture as Rems.... has failed in every test they have run so far.
To me it is like comparing an Aston-Martin to a Yugo.
Total waste of $2B for Rems... dosages put in inventory IMO
SI for Brilacidin 300+, Rems about 130.
To me, that is not comparable.
I am starting to believe that IPIX operates in a realm closely resembling a ninja. We are building a massive case for wildly successful drugs (especially Brilacidin at the current time) in plain sight of everyone but nobody appears to have noticed.
I do not take this as a lack of management skills nor a conscious attempt by medicine to trivialize IPIX and our products. It is simply that IPIX has not reached the point with its drugs to have merited much notice to date, at least as far as big medicine is concerned.
One of the most eye opening posts ever was just recently made when it was revealed by a poster that his relative, a high executive at a major NYC hospital, told him that they don't even become aware of a product prior to verifiable data as evidenced by peer reviewed articles or results of human trials. Company PRs mean nothing to them.
Thus, though we on this board know (or at least we think we know) everything about Brilacidin for CV and other indications, we have not yet reached the point that big medicine has become aware of us.
That point is rapidly approaching and we have planned well for it with the appointment today of Dr. DeGrado as a scientific advisor, the recent SI results of 300+ for Brilacidin vs CV19, many tests run by the government's own regional bio lab that were so impressive that the lab co-applied with us for a PAN-CORONA grant, prior ABSSSI human trials reflecting the safety of B, etc. We have steadily built our position, but step by step it has gone under the radar of big medicine and seemingly big government.
That will be changing soon when the RBL results are published, the pre-peer review article is published, grant money is received from the government, and a human trial is finalized.
Even all the above may still leave Brilacidin under the radar somewhat as we never know what news big media will run with and they may ignore B for the time being.
But the results of the human trials, and IMO even earlier the indications from early patients (maybe only a day or two after receiving the B IV) will give a very good indication that B is extremely effective as a CV19 treatment.
This is what will blow the minds of big medicine IMO. If we get wide publicity prior to this, great, but I am only interested in how B is viewed after the human trial patients react to it.
I am extremely confident at that time our stock price will rise tremendously. Until then, still at the mercy of the MMs and algorithms that seem to be intent on keeping the IPIX share price at the current levels.
So let IPIX continue to add to its arsenal and even if these continuing successes seem to go unnoticed, know that soon every small step forward will prove of major importance to the tremendous acceptance by big medicine to Brilacidin.
Keep the eye on the war, not on the battle. If IPIX were a fighter, it would have landed MANY body shots thru the early and mid rounds but has yet to land the killer blow. But as we near the final rounds, all those body blows already landed will prove to be the catalyst for IPIX to launch a haymaker against anyone standing against Brilacidin.
I don't have a free account and I get edits on all posts. The button should be just to the left of the next/previous buttons and it is in red with the amount of time remaining to be able to edit shown.
Make a reply to this and see right away if you have an edit button. You don't have to make any changes if you hit the edit, just cancel. so no harm.
You have 10 or 15 minutes to edit a post as many times as you like so you don't have to make a number of posts correcting the original.
When you click on your post within the edit time frame, an edit button appears. Click it and your post comes up. Make all corrections and hit the submit post button.
It will then reappear with the corrections made.
What have you found disappointing? Brilacidin has been moving forward steadily since Feb.
Maybe not as fast as some would prefer, maybe even being held back due to lack of greasing the wheels with lobbyists as the BPs have done, but moving forward nevertheless.
The science is still the same, the results are screaming that B will be a major success in human trials, and after trial results are made known then nothing can hold B back.
Now combine the results of the testing, the success shown on lung issues (COPD,Asthma), kidney issues, brain swelling issues, virus issues, etc and then add the expected results of the human trial and 2020 was a BANNER YEAR for both Brilacidin and IPIX. To top it off, we also have succeeded enormously on the financial side. We have about $5-6MM cash still on hand or something like that, we have assured funding from Aspire for being able to handle ourselves any and all trials for other indications we plan on starting, and we should have money starting to flow in from grants/other countries/private sources wishing to better the world in medical ways.
I personally am quite disturbed by the many longs moaning and groaning now as we are progressing so rapidly beyond what anyone could have imagined for IPIX/Brilacidin at the start of the year it isn't even funny.
So we are looking at something around 8 weeks to get some feedback from human trials IMO.
That should start this juggernaut rolling and I also believe we proceed in Q4 on other indication trials (OM, IBD) and make progress on perfecting and tox testing the Kevetrin pill.
All this with only one actual employee doing everything. Amazing.
Most are expecting a successful human trial within 8 weeks. Who can't wait that long? I say this as IMO the political powers want a success story, a real one for a change, regarding treatment for CV19 prior to the election in Nov. B is that treatment IMO.
I agree that is the most likely (and only) PR that will move the share price monumentally. At this point, I do not believe even a grant would do much to move the price unless it was for 10s of millons (which is definitely what B deserves, many 10s).
The only other possible share price mover PR IMO is a major media fixation on Brilacidin due to some governmental spokesman raving about its potential.
I consider you an EF Hutton poster. I listen closely to what you have to say. Gives me great confidence in you expecting such great things from Brlacidin
I am with you that it seems a bit early for this to be Brilacidin, especially since we haven't had any human trial results to positively affirm it will work as shown it should in all tests to date.
But then again, could there have been unannounced major work being done w/ patients over the last few weeks? Many here have questioned the speed of advancement seemingly pretty slow for such promising early test results.
If it is not B, I believe that when our trial gets finished (and all testing on B gets completed) that it will be hard for any competitor to prove as effective and safe as Brilacidin should prove. Also hope B has a price advantage as well.
Exciting times.
Glad to hear things appear to be going good for you and your knee now. Health is even more important than finances.
Also appreciate the PM and hope things work out well for IPIX, which IMO should have wonderful odds of happening.
Am on the road myself until next weekend so will be here very little over the next week. Expect it to be the start of a very good remainder of 2020 for IPIX stockholders.
Have my position locked in and expect favorable news to start coming out on a regular basis for the remainder of the year so that the value of it will increase steadily.
Hope to hear something this week, expect some sort of news, but if it doesn't happen that won't bother me any. Time is on our side.
My take on gaps. They are simply another tool employed by MMs in thinly traded stocks that they control to be able to run the stock price up and down at will.
Kill the share price, then open one day w/ a gap, and let the stock price run up knowing that many will always expect the gap to fill some days/weeks/months/years down the line.
More of their BS tools that they know will be effective with the "herd" mentality of the investing public.
The famous line that "a sucker is born every minute" applies well to investors IMO.
We received the info posted on the website, but not all the info needed to answer your question. I am sure there is some sort of time frame discussed in the agreement, AS paid us a small upfront amount of cash but the milestones are what triggers further payments up to $24MM, but still unknown are all other discussions as to what is considered "successful marketing" of B for UP/UPS, and the actual specifics of the Right of First Refusal. I am sure IPIX covered it's B property rights to the hilt as Leo knows its full value.
The IBD indications for UC/Crohn's and other conditions will bring a very heavy price and whether AS has the assets and the determination to outbid all others for it has many in doubt, me among them. If they pay the price, though, I don't have anything against them. It is not as if any other BP has done squat to earn a seat at the IPIX dinner table yet.
In the past week or so there was some question about IPIX's agreement with Alfasigma as to rights granted to AS. The following is a copy from the company website under "About", then "Collaborations":
On July 22, 2019, Innovation completed a license agreement with Alfasigma S.p.A, granting the company exclusive rights to develop and commercialize locally-administered Brilacidin (e.g., foam, enema, gel), on a worldwide basis, for the treatment of Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS) in Inflammatory Bowel Disease (IBD). As part of the agreement, Innovation is eligible to receive over $24M in initial and milestone-based payments, and a 6 percent royalty (net sales) based on the successful marketing of Brilacidin for UP/UPS. The agreement also includes a Right of First Refusal for Brilacidin for the treatment of more extensive forms of IBD, such as Ulcerative Colitis and Crohn’s Disease, and a Right of First Negotiation for Brilacidin in other Gastrointestinal indications.
AS said way back in late 2019 they were not planning a P3 for UP/UPS until sometime in the middle of 2020 so they aren't in arrears as to getting a trial going by now.
Some think AS shouldn't go for the P3 (financial reasons) until the P2 UC trial is completed because if the pill is deemed effective for both UC/Crohn's then it would likely work against UP/UPS as well and that brings to question whether a foam/gel/etc would be able to compete with the pill delivery system.
You are correct, IPIX gave no rights whatsoever to AS in regards to CV, only UP/UPS indications.
What I remember is that they have worldwide distribution rights for UP/UPS in gel, foam, or some other like delivery system.
I thought they had some other rights of last refusal regarding other parts of the IBD indication but reading the Oct14 PR and 1 other PR I couldn't find any mention of it.
Might have been in a filing somebody read (as I don't read filings)and posted to the board.
Leo didn't announce GMU as the RBL, that info came about from a GMU PR. So GMU let the cat out of the bag. Leo has done everything by the book.
Things are progressing, I am sure, but until the money firms up more Leo is keeping things close to the vest and I like this tactic. No need to be letting possible partners know our plans until they need to be known. Gives Leo a stronger negotiating position IMO.
OM advancement could be based on grants received so things currently could be on hold until Leo has a better idea of which direction he wants to go (partner prior to P3, after P3, or other) This should be a fairly inexpensive trial so IMO Leo will want to do it alone. Results of P3 could cause Leo to decide to take OM commercial alone - always an option as there is no competitor, delivery system very simple, distribution should be easy w/ sachets.
IBD has been mentioned that a P2 was expected in Q3 but then CV put everything on hold so IMO very good chance a P2 will start pretty soon in Q4. Again, I think IPIX does this alone and when very good results come back the value of B-IBD will have skyrocketed and then the time for a partnership may start taking hold. Definitely expect a partner for IBD.
Proctitis thru AS - Leo at the mercy of what AlphaSigma wants to do as to progress - they (AS) may wait to see how the P2 UC trial goes prior to doing their trial
Kevetrin - Again, money is the issue. I am sure leo wants to get the pill tox tests finalized ASAP so we can test the pill on healthy volunteers so pill could be used in complementary tests with current cancer treatments.
Who knows if Leo is thinking of franchising out most all indications and if he would prefer working with one main partner rather than a whole slew of different organizations and cultures.
For years we have only been along for the ride, now IPIX (especially if CV turns out very positive) is squarely in the drivers seat. No need to hurry, things are progressing nicely IMO
A great SI score would be wonderful, but it is just an indicator. The results of the human trial is the pot of gold.
I take an excellent SI score as a given, just like what we have shown in the results of the human tissue tests.